Cochrane · systematic review · CD004102
Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection)
Vallejo, M, Reyes, PPA, Martinez Garcia, M, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
5
No studies
7
Included studies
NR
No studies 7 · 58.3%Ungraded 0 · 0%Very low 2 · 16.7%Low 2 · 16.7%Moderate 1 · 8.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC
Population: adults with both late‐stage, symptomatic Chagas disease and CCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearance or reduction of antibody titres (N) (a) at 12 months (b) at 2 years (c) at 5 years Benznidazole vs placebo | RR 1.91 [1.64, 2.21] | 1 study · 1896 participants | Low Downgraded: risk of bias, imprecision |
Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) Benznidazole vs placebo | OR 31.66 [10.56, 94.97] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Pathological demonstration of tissue parasites (N) Benznidazole vs placebo | no estimate extracted | NR | No studies |
Clinical improvement (N) (a) Heart failure (b) Sustained ventricular tachycardia Benznidazole vs placebo | RR 0.89 [0.69, 1.14] | 1 study · 2854 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Benznidazole vs placebo | no estimate extracted | NR | No studies |
Adverse events (N) Benznidazole vs placebo | RR 2.52 [2.09, 3.03] | 1 study · 2854 participants | Moderate Downgraded: risk of bias, imprecision |
Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC
Population: adults with both late‐stage, symptomatic Chagas disease and CCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearance or reduction of antibody titres (N) Nifurtimox vs placebo | RR 16.89 [2.44, 116.85] | 1 study · 51 participants | Very low Downgraded: risk of bias, imprecision |
Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) Nifurtimox vs placebo | no estimate extracted | NR | No studies |
Pathological demonstration of tissue parasites (N) Nifurtimox vs placebo | no estimate extracted | NR | No studies |
Clinical improvement (N) Nifurtimox vs placebo | no estimate extracted | NR | No studies |
Quality of life Nifurtimox vs placebo | no estimate extracted | NR | No studies |
Adverse events (N) Nifurtimox vs placebo | no estimate extracted | NR | No studies |